Topical cyclosporine A 0.05 % in the treatment of keratoconjunctivitis sicca;Ciclosporin A 0,05 % Augentropfen zur Therapie der Keratokonjunktivitis sicca

Klinische Monatsblatter fur Augenheilkunde

Volumn 229, Issue 5, 2012, Pages 548-553

  Schrell, C ^a   Cursiefen, C ^a   Kruse, F ^a   Jacobi, C ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

causal therapy; conjunctiva; cornea; cyclosporine A; dry eye; inflammation

Indexed keywords

ARTIFICIAL TEAR; CYCLOSPORIN A; EYE DROPS; FLUORESCEIN; HYALURONIC ACID; ROSE BENGAL;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; INTRAOCULAR PRESSURE; JONES TEST; KERATOCONJUNCTIVITIS SICCA; MAJOR CLINICAL STUDY; OCULAR SURFACE DISEASE INDEX; OFF LABEL DRUG USE; PARAMETERS; PROCEDURES; STAINING; TEAR BREAK UP TIME; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS SICCA; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84861231529     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0031-1281862     Document Type: Article

References (31)

1. Jacobi C, Dietrich T, Cursiefen C et al. Das trockene Auge. Ophthalmologe: 2006; 103 9 17
2. DEWS Definition and Classification of Dry Eye. Report of the Diagnosis and Classification Subcommittee of the Dry Eye WorkShop. Ocul Surf: 2007; 5 75 139
3. Luo L, Li DQ, Doshi A et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signalling pathways on the ocular surface. Invest Ophthalmol Vis Sci: 2004; 45 4293 4301 (Pubitemid 39564653)
4. Kymionis GD, Bouzoukis DI, Diakonis VF et al. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol: 2008; 2 829 836
5. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol: 2000; 118 1264 1268
6. Pflugfelder SC, Tseng SC, Sanabria O et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea: 1998; 17 38 56 (Pubitemid 28047008)
7. Pflugfelder SC. Anti-inflammatory therapy for dry eye. Am J Ophthalmol: 2004; 137 337 342
8. Cursiefen C, Jacobi C, Dietrich T et al. Aktuelle Therapie des trockenen Auges. Ophthalmologe: 2006; 103 18 24 (Pubitemid 43170302)
9. Jacobi C, Bellios N, Jacobi A et al. Erhebungsbogen zur Anamnese und Diagnostik des trockenen Auges. Klin Monbl Augenheilkd 14.04.2010, online Publikation
10. Jacobi C, Wenkel H, Jacobi A et al. Hepatitis C and Ocular Surface Disease. Am J Ophthalmol: 2007; 144 705 711
11. Niederkorn JY, Stern ME, Pflugfelder SC et al. Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratokonjunktivitis. J Immunol: 2006; 176 3950 3957 (Pubitemid 44264372)
12. Behrens A, Doyle JJ, Stern L et al. Dysfunctional tear syndrome. A Delphi approach to treatment recommendations. Cornea: 2006; 25 90 97
13. Höh H, Schirra F, Kienecker C et al. Lidkantenparallele conjunktivale Falten sind ein sicheres diagnostisches Zeichen des trockenen Auges. Ophthalmologe: 1995; 92 802 808 (Pubitemid 26027999)
14. Pflugfelder SC, Maskin SL, Anderson B et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0,5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol: 2004; 138 444 457 (Pubitemid 39208573)
15. Wilson SE. Inflammation: a unifying theory for the origin of dry eye syndrome. Manag Care: 2003; 12 14 19
16. Stonecipher K, Perry HD, Gross RH et al. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin: 2005; 21 1057 1063 (Pubitemid 41032695)
17. Gumus K, Cavanagh DH. The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca. Clin Ophthalmol: 2009; 3 57 67
18. Kunert KS, Tisdale AS, Stern ME et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol: 2000; 118 1489 1496
19. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol: 2002; 120 330 337 (Pubitemid 34250055)
20. Perry HD, Solomon R, Donnenfeld ED et al. Evaluation of Topical Cyclosporine for the Treatment of Dry Eye Disease. Arch Ophthalmol: 2008; 126 1046 1050
21. Stevenson OD, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate to severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporine A Phase 2 Study Group. Ophthalmology: 2000; 107 967 974
22. Toshida H, Nguyen DH, Beuerman RW et al. Neurologic Evaluation of Acute Lacrimomimetic Effect of Cyclosporine in an Experimental Rabbit Dry Eye Model. Invest Ophthalmol Vis Sci: 2009; 50 2736 2741
23. Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol: 1989; 107 1210 1216 (Pubitemid 19195651)
24. Laibovitz RA, Solch S, Andrianao J. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea: 1993; 12 315 323 (Pubitemid 23182127)
25. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol: 2004; 15 299 304 (Pubitemid 38962108)
26. Sall K, Stevenson OD, Mundorf TK et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology: 2000; 107 631 639 (Pubitemid 30191329)
27. Abelson M, Ousler G, Nally LA et al. Alternate reference values for tear film break-up time in normal and dry eye populations. Adv Exp Med Biol: 2002; 506 1121 1125 (Pubitemid 36308309)
28. Smith RE. The tear film complex: pathogenesis and emerge in therapies for dry eyes. Cornea: 2005; 24 1 7 (Pubitemid 40053488)
29. Stern ME, Beuerman RW, Fox RI et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea: 1998; 17 584 589 (Pubitemid 28511901)
30. Tomlinson A, Khanal S, Ramaesh K et al. Tear film osmolarity: determination of a referent value for dry eye diagnosis. Invest Ophthalmol Vis Sci: 2006; 47 4309 4315 (Pubitemid 46579353)
31. Schechter BA. Ketorolac During the Induction Phase of Cyclosporin-A Therapy. J Ocul Pharmacol Ther: 2006; 22 150 154 (Pubitemid 43742952)